PPARG and obesity due to melanocortin 4 receptor deficiency: As mentioned in introduction, PPARγ has been identified as a therapeutic target for obesity, hyperlipidaemia and diabetes for the dual functions of regulating glycolipid metabolism [28, 29] and inhibiting inflammation [30, 31].